AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.
View Top Employees from AzurRx BioPharmaWebsite | http://www.azurrx.com |
Ticker | AZRX |
Revenue | $3 million |
Funding | $33.8 million |
Employees | 17 (17 on RocketReach) |
Founded | 2014 |
Address | 1615 S Congress Ave, Ste 103, Delray Beach, Florida 33445, US |
Phone | (646) 699-7855 |
Technologies |
JavaScript,
HTML,
PHP
+23 more
(view full list)
|
Industry | Drug Manufacturing & Research, Biotechnology, Lipase, Pharmaceuticals, Science and Engineering, Non-sytemic therapies, Healthcare, Health Care, Recombinant proteins, Pharmaceutical |
Web Rank | 11 Million |
Keywords | Azurrx Biopharma, Prolong Pharmaceuticals Careers |
Competitors | ARCA biopharma, Inc., Cue Biopharma, Inc., DiaMedica Therapeutics Inc., Precision Biologics, Soligenix, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular AzurRx BioPharma employee's phone or email?
The AzurRx BioPharma annual revenue was $3 million in 2023.
Christine Rigby is the President and Chief Operating Officer of AzurRx BioPharma.
17 people are employed at AzurRx BioPharma.
AzurRx BioPharma is based in Delray Beach, Florida.
The NAICS codes for AzurRx BioPharma are [32541, 325, 32, 3254].
The SIC codes for AzurRx BioPharma are [28, 283].